NICE recommends against Aimovig from Novartis

By Shannon Lehnbeuter | Jan 17, 2019 | 5:28 PM GMT

The U.K.’s NICE issued draft guidance not recommending Aimovig erenumab from Novartis AG (NYSE:NVS; SIX:NOVN) to prevent chronic and episodic

Read the full 207 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE